RxDoctor Payments Data

Edward Juarez, MD

Internal Medicine · El Paso, TXNPI 1285625400

Payments from drug & device makers

$6,779in general payments, 2019–2025

Across 84 payments — averaging $80.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Merz North America, Inc.$861
  • Globus Medical$746
  • Abbott$706
  • Nevro Corp.$460
  • Boehringer Ingelheim$440
  • plus $3K from 12 others

What the payments were for

  • Food & beverage$6,779100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,779 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$10,318
Medicare patients
35
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin273$412,735
OzempicSemaglutide107$177,577
JanuviaSitagliptin Phosphate103$157,109
TrulicityDulaglutide70$146,019
MounjaroTirzepatide82$127,772
EliquisApixaban79$72,528
Bydureon BciseExenatide Microspheres24$59,041
ProliaDenosumab27$45,971
FarxigaDapagliflozin Propanediol24$35,244
MyrbetriqMirabegron28$25,280
Lantus SolostarInsulin Glargine,hum.Rec.Anlog126$23,314
XareltoRivaroxaban11$21,138
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$16,173
TradjentaLinagliptin11$15,461
VascepaIcosapent Ethyl13$13,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$440$428,196284 claims
Lilly USA, LLCTrulicity, Mounjaro$223$273,791152 claims
Novo NordiskOzempic$315$177,577107 claims
Johnson & JohnsonXarelto$113$21,13811 claims
Sanofi-aventis U.S. LLCLantus$17$7,15631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →